Abstract
Background/Objectives:
Neuropeptide Y (NpY) is an important factor in neuropeptide signalling, and significantly change in the blood and cerebrospinal fluid (CSF) during chronic kidney disease (CKD) progression. However, the role of NpY remains unclear. We aimed to investigate the associations between NpY levels, nutritional status and cardiovascular disease (CVD) in patients with CKD.
Subjects/Methods:
In this cohort study, we performed Pearson's correlation analysis and multiple linear regressions to assess the relationship between CSF and serum NpY levels, as well as nutritional indices. Receiver operating characteristic curves were used to evaluate the sensitivity and specificity of CSF NpY levels. As NpY affects the cardiovascular system, Kaplan–Meier analysis was used to investigate the relationship between serum NpY levels and CVD.
Results:
CSF NpY levels and nutritional indices were related during CKD progression (energy intake: β=0.236, P<0.001; mid-arm muscle circumference: β=0.953, P=0.014; prealbumin: β=0.067, P<0.001), and had high specificity (79.9%). High serum NpY levels may be a risk factor associated with CVD (relative risk=1.8015, 95% confidence interval: 1.0509–3.0881).
Conclusions:
Our results suggested a relationship between CSF NpY levels and nutritional indices in CKD patients. High serum NpY concentrations may be a risk factor associated with CVD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cheung WW, Paik KH, Mak RH . Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol 2010; 25: 711–724.
Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B . Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr Opin Lipidol 2009; 20: 3–9.
Foster BJ, Leonard MB . Measuring nutritional status in children with chronic kidney disease. Am J Clin Nutr 2004; 80: 801–814.
Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int 2013; 84: 1096–1107.
Kovesdy CP, Kalantar-Zadeh K . Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009; 29: 3–14.
Mastrangelo A, Paglialonga F, Edefonti A . Assessment of nutritional status in children with chronic kidney disease and on dialysis. Pediatr Nephrol 2014; 29: 1349–1358.
Edwardson JA, Hough CA . The pituitary-adrenal system of the genetically obese (ob/ob) mouse. J Endocrinol 1975; 65: 99–107.
Hanson ES, Dallman MF . Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995; 7: 273–279.
de Piano A, Tock L, Carnier J, Oyama LM, Oller do Nascimento CM, Martinz AC et al. Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. Metabolism 2010; 59: 613–619.
Colmers WF, El Bahh B . Neuropeptide Y and epilepsy. Epilepsy Curr 2003; 3: 53–58.
Song J, Li H, Zhang XD . Influence of different blood purification treatment on the serum leptin and neuropeptide Y levels in patients with chronic renal failure. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010; 26: 1116–1118.
Deng C, Wei LB, Huang LW . Effects of Shenshuai Yangzhen capsule on hypothalamic leptin-neuropeptide and proopiomelanocortin axes in chronic renal failure rats with malnutrition. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010; 30: 952–956.
Bald M, Gerigk M, Rascher W . Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 1997; 30: 23–27.
Mitch WE . Cachexia in chronic kidney disease: a link to defective central nervous system control of appetite. J Clin Invest 2005; 115: 1476–1478.
Kalantar-Zadeh K . Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Semin Dial 2005; 18: 365–369.
Group KW . KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53: S11–104.
Snyder JJ, Collins AJ . KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999–2004. Am J Nephrol 2009; 30: 44–54.
Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y et al. Modified glomerular filtration rate estimating equation. J Am Soc Nephrol 2006; 17: 2937–2944.
Nelson EE, Hong CD, Pesce AL, Peterson DW, Singh S, Pollak VE . Anthropometric norms for the dialysis population. Am J Kidney Dis 1990; 16: 32–37.
Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2258–2268.
Kelemen LE, Anand SS, Vuksan V, Yi Q, Teo KK, Devanesen S et al. Development and evaluation of cultural food frequency questionnaires for South Asians, Chinese, and Europeans in North America. J Am Diet Assoc 2003; 103: 1178–1184.
Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC . A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transplant 1999; 14: 1732–1738.
Steiber AL, Kalantar-Zadeh K, Secker D, McCarthy M, Sehgal A, McCann L . Subjective Global Assessment in chronic kidney disease: a review. J Ren Nutr 2004; 14: 191–200.
Vero LM, Byham-Gray L, Parrott JS, Steiber AL . Use of the subjective global assessment to predict health-related quality of life in chronic kidney disease stage 5 patients on maintenance hemodialysis. J Ren Nutr 2013; 23: 141–147.
Winaver J, Abassi Z . Role of neuropeptide Y in the regulation of kidney function. EXS 2006; 95: 123–132.
Adamczak M, Kokot F, Witkowicz J, Wiecek A . Plasma neuropeptide Y concentration in kidney transplant patients during the early posttransplant period. Ann Transplant 2004; 9: 37–39.
Cheung WW, Rosengren S, Boyle DL, Mak RH . Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 2008; 74: 180–186.
Roberts TK, Bailey JL . Beyond nutrition: neuropeptide signaling and muscle mass maintenance in chronic kidney disease. Kidney Int 2008; 74: 143–145.
Mak RH, Cheung W . Cachexia in chronic kidney disease: role of inflammation and neuropeptide signaling. Curr Opin Nephrol Hypertens 2007; 16: 27–31.
Bokarewa MI, Erlandsson MC, Bjersing J, Dehlin M, Mannerkorpi K . Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia. Mediators Inflamm 2014; 2014: 627041.
Plata-Salaman CR . Leptin (OB protein), neuropeptide Y, and interleukin-1 interactions as interface mechanisms for the regulation of feeding in health and disease. Nutrition 1996; 12: 718–719.
Erickson JC, Clegg KE, Palmiter RD . Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415–421.
Mak RH, Cheung W, Cone RD, Marks DL . Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006; 69: 794–797.
Pardridge WM . Mechanisms of neuropeptide interaction with the blood-brain barrier. Ann NY Acad Sci 1986; 481: 231–249.
Foster BJ, Kalkwarf HJ, Shults J, Zemel BS, Wetzsteon RJ, Thayu M et al. Association of chronic kidney disease with muscle deficits in children. J Am Soc Nephrol 2011; 22: 377–386.
Morley JE, Farr SA . Cachexia and neuropeptide Y. Nutrition 2008; 24: 815–819.
Tsuda K . Neuropeptide Y and sympathetic nervous system in blood pressure regulation. Hypertension 2003; 42: e13–e14 (author reply).
Krukoff TL . Neuropeptide regulation of autonomic outflow at the sympathetic preganglionic neuron. Anatomical and neurochemical specificity. Ann NY Acad Sci 1990; 579: 160–167.
Maturi MF, Greene R, Speir E, Burrus C, Dorsey LM, Markle DR et al. Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs. J Clin Invest 1989; 83: 1217–1224.
Liu L, Xie S, Liao X, Zhang L, Zhong L . Netrin-1 pretreatment protects rat kidney against ischemia/reperfusion injury via suppression of oxidative stress and neuropeptide Y expression. J Biochem Mol Toxicol 2013; 27: 231–236.
Riera M, Torras J, Cruzado JM, Lloberas N, Liron J, Herrero I et al. The enhancement of endogenous cAMP with pituitary adenylate cyclase-activating polypeptide protects rat kidney against ischemia through the modulation of inflammatory response. Transplantation 2001; 72: 1217–1223.
Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, Treuer AV, Lamirault G, Dulce R et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 2604–2609.
Ali F, Raufi MA, Washington B, Ghali JK . Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev 2007; 25: 261–279.
Yang YF, Yang LH, Shi GP, Han QD . Platelet neuropeptide Y and its vasoconstriction effect in rat. Sheng Li Xue Bao 1993; 45: 400–404.
Zhou JR, Zhang LD, Wei HF, Wang X, Ni HL, Yang F et al. Neuropeptide Y induces secretion of high-mobility group box 1 protein in mouse macrophage via PKC/ERK dependent pathway. J Neuroimmunol 2013; 260: 55–59.
Kawanaka N, Taylor AW . Localized retinal neuropeptide regulation of macrophage and microglial cell functionality. J Neuroimmunol 2011; 232: 17–25.
Acknowledgements
This research is supported by the National Science Foundation of China (Nos. 81173457 and 81001674).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
We declare that we have no financial or personal relationships with other people or organisations that can inappropriately influence our work; there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, this manuscript.
Additional information
Supplementary Information accompanies this paper on European Journal of Clinical Nutrition website
Rights and permissions
About this article
Cite this article
Lu, L., Zou, YC., Wang, M. et al. Neuropeptide Y levels are associated with nutritional status and cardiovascular events in adults with chronic kidney disease. Eur J Clin Nutr 69, 717–721 (2015). https://doi.org/10.1038/ejcn.2015.67
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2015.67